506 related articles for article (PubMed ID: 12563309)
1. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
Chène P
Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
3. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
4. The MDM2 RING-finger domain is required to promote p53 nuclear export.
Geyer RK; Yu ZK; Maki CG
Nat Cell Biol; 2000 Sep; 2(9):569-73. PubMed ID: 10980696
[TBL] [Abstract][Full Text] [Related]
5. Activation and activities of the p53 tumour suppressor protein.
Bálint E E; Vousden KH
Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
[TBL] [Abstract][Full Text] [Related]
6. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM; Spicer JF; Barnes DM; Lane DP
Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
[TBL] [Abstract][Full Text] [Related]
8. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
Xirodimas DP; Stephen CW; Lane DP
Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
[TBL] [Abstract][Full Text] [Related]
9. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
10. The contribution of the RING finger domain of MDM2 to cell cycle progression.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2000 Aug; 19(34):3849-57. PubMed ID: 10951578
[TBL] [Abstract][Full Text] [Related]
11. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.
Wasylyk C; Salvi R; Argentini M; Dureuil C; Delumeau I; Abecassis J; Debussche L; Wasylyk B
Oncogene; 1999 Mar; 18(11):1921-34. PubMed ID: 10208414
[TBL] [Abstract][Full Text] [Related]
12. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
Maréchal V
Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
[TBL] [Abstract][Full Text] [Related]
13. PML regulates p53 stability by sequestering Mdm2 to the nucleolus.
Bernardi R; Scaglioni PP; Bergmann S; Horn HF; Vousden KH; Pandolfi PP
Nat Cell Biol; 2004 Jul; 6(7):665-72. PubMed ID: 15195100
[TBL] [Abstract][Full Text] [Related]
14. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
[TBL] [Abstract][Full Text] [Related]
15. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
16. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
17. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang Y; Xiong Y
Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
19. p53 and MDM2: antagonists or partners in crime?
Eischen CM; Lozano G
Cancer Cell; 2009 Mar; 15(3):161-2. PubMed ID: 19249672
[TBL] [Abstract][Full Text] [Related]
20. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
Dubs-Poterszman MC; Tocque B; Wasylyk B
Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
